Breaking News, Financial News

Novo Nordisk 3Q

In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novo Nordisk 3Q09 3Q Revenues: $2.5 billion (+11%) 3Q Earnings: $539.7 million (+3%) YTD Revenues: $7.4 billion (+16%) YTD Earnings: $1.7 million (+21%) Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were up 20%. Sales in Europe were up 2%. International Operations were up 10% and Japa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters